|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar
|
|
3
|
Marur S and Forastiere AA: Head and neck
cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin
Proc. 83:489–501. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vermorken JB and Specenier P: Optimal
treatment for recurrent/ metastatic head and neck cancer. Ann
Oncol. 21(Suppl 7): vii252–vii261. 2010. View Article : Google Scholar
|
|
5
|
Kuczynski EA, Sargent DJ, Grothey A and
Kerbel RS: Drug rechallenge and treatment beyond
progressionimplications for drug resistance. Nat Rev Clin Oncol.
10:571–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joe AK, Liu H, Suzui M, Vural ME, Xiao D
and Weinstein IB: Resveratrol induces growth inhibition, S-phase
arrest, apoptosis and changes in biomarker expression in several
human cancer cell lines. Clin Cancer Res. 8:893–903.
2002.PubMed/NCBI
|
|
9
|
Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC,
Groc L, Rodriguez AI, Koubi D, Hunter TJ, Corcoran GB, et al:
Resveratrol-induced apoptotic death in human U251 glioma cells. Mol
Cancer Ther. 4:554–561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buhrmann C, Shayan P, Kraehe P, Popper B,
Goel A and Shakibaei M: Resveratrol induces chemosensitization to
5-fluorouracil through up-regulation of intercellular junctions,
Epithelial-to-mesenchymal transition and apoptosis in colorectal
cancer. Biochem Pharmacol. 98:51–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen M, Wu RX, Zhao L, Li J, Guo HT, Fan
R, Cui Y, Wang YM, Yue SQ and Pei JM: Resveratrol attenuates
ischemia/reperfusion injury in neonatal cardiomyocytes and its
underlying mechanism. PLoS One. 7:e512232012. View Article : Google Scholar
|
|
12
|
Ku CR, Lee HJ, Kim SK, Lee EY, Lee MK and
Lee EJ: Resveratrol prevents streptozotocininduced diabetes by
inhibiting the apoptosis of pancreatic β-cell and the cleavage of
poly (ADP-ribose) polymerase. Endocr J. 59:103–109. 2012.
View Article : Google Scholar
|
|
13
|
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr
and Walle UK: High absorption but very low bioavailability of oral
resveratrol in humans. Drug Metab Dispos. 32:1377–1382. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramasamy T, Kim JH, Choi JY, Tran TH, Choi
HG, Yong CS and Kim JO: pH sensitive polyelectrolyte complex
micelles for highly effective combination chemotherapy. J Material
Chem B. 2:63242014. View Article : Google Scholar
|
|
15
|
Hare JI, Lammers T, Ashford MB, Puri S,
Storm G and Barry ST: Challenges and strategies in anti-cancer
nanomedicine development: An industry perspective. Adv Drug Deliv
Rev. 108:25–38. 2017. View Article : Google Scholar
|
|
16
|
Sundaramoorthy P, Ramasamy T, Mishra SK,
Jeong KY, Yong CS, Kim JO and Kim HM: Engineering of
caveolae-specific self-micellizing anticancer lipid nanoparticles
to enhance the chemotherapeutic efficacy of oxaliplatin in
colorectal cancer cells. Acta Biomater. 42:220–231. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allen TM and Cullis PR: Liposomal drug
delivery systems: From concept to clinical applications. Adv Drug
Deliv Rev. 65:36–48. 2013. View Article : Google Scholar
|
|
18
|
Kneidl B, Peller M, Winter G, Lindner LH
and Hossann M: Thermosensitive liposomal drug delivery systems:
State of the art review. Int J Nanomed. 9:4387–4398. 2014.
|
|
19
|
Mohan A, Narayanan S, Balasubramanian G,
Sethuraman S and Krishnan UM: Dual drug loaded nanoliposomal
chemotherapy: A promising strategy for treatment of head and neck
squamous cell carcinoma. Eur J Pharm Biopharm. 99:73–83. 2016.
View Article : Google Scholar
|
|
20
|
Ramasamy T, Ruttala HB, Gupta B, Poudel
BK, Choi HG, Yong CS and Kim JO: Smart chemistry-based nanosized
drug delivery systems for systemic applications: A comprehensive
review. J Control Release. 258:226–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramasamy T, Haidar ZS, Tran TH, Choi JY,
Choi HG, Yong CS and Kim JO: Layer-by-layer assembly of liposomal
nanoparticles with PEGylated polyelectrolytes enhances systemic
delivery of multiple anticancer drugs. Acta Biomaterialia.
10:5116–5127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosi NL and Mirkin CA: Nanostructures in
biodiagnostics. Chem Rev. 105:1547–1562. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sheng Q and Liu J: The therapeutic
potential of targeting the EGFR family in epithelial ovarian
cancer. Br J Cancer. 104:1241–1245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vidal F, de Araujo WM, Cruz AL, Tanaka MN,
Viola JP and Morgado-Díaz JA: Lithium reduces tumorigenic potential
in response to EGF signaling in human colorectal cancer cells. Int
J Oncol. 38:1365–1373. 2011.PubMed/NCBI
|
|
25
|
Acharya S, Dilnawaz F and Sahoo SK:
Targeted epidermal growth factor receptor nanoparticle
bioconjugates for breast cancer therapy. Biomaterials.
30:5737–5750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen L, She X, Wang T, He L, Shigdar S,
Duan W and Kong L: Overcoming acquired drug resistance in
colorectal cancer cells by targeted delivery of 5-FU with EGF
grafted hollow meso-porous silica nanoparticles. Nanoscale.
7:14080–14092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim MW, Jeong HY, Kang SJ, Choi MJ, You
YM, Im CS, Lee TS, Song IH, Lee CG, Rhee KJ, et al: Cancer-targeted
nucleic acid delivery and quantum dot imaging using EGF receptor
aptamer-conjugated lipid nanoparticles. Sci Rep. 7:94742017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu
Y and Gu J: Identification and characterization of a novel peptide
ligand of epidermal growth factor receptor for targeted delivery of
therapeutics. FASEB J. 19:1978–1985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peer D, Karp JM, Hong S, Farokhzad OC,
Margalit R and Langer R: Nanocarriers as an emerging platform for
cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar
|
|
30
|
Liu D and Auguste DT: Cancer targeted
therapeutics: From molecules to drug delivery vehicles. J Control
Release. 219:632–643. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang WC, Chen SH, Chiang WH, Huang CW, Lo
CL, Chern CS and Chiu HC: Tumor microenvironment-responsive
nanoparticle delivery of chemotherapy for enhanced selective
cellular uptake and transportation within tumor. Biomacromolecules.
17:3883–3892. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Field LD, Nag OK, Sangtani A, Burns KE and
Delehanty JB: The role of nanoparticles in the improvement of
systemic anticancer drug delivery. Ther Deliv. 9:527–545. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruttala HB, Chitrapriya N, Kaliraj K,
Ramasamy T, Shin WH, Jeong JH, Kim JR, Ku SK, Choi HG, Yong CS and
Kim JO: Facile construction of bioreducible crosslinked polypeptide
micelles for enhanced cancer combination therapy. Acta Biomater.
63:135–149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu Y, Wang S, Chan HF, Liu Y, Li H, He C,
Li Z and Chen M: Triphenylphosphonium-modified poly(ethylene
glycol)-poly(ε-caprolactone) micelles for mitochondria- targeted
gambogic acid delivery. Int J Pharm. 522:21–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sundaramoorthy P, Baskaran R, Mishra SK,
Jeong KY, Oh SH, Kyu Yoo B and Kim HM: Novel self-micellizing
anticancer lipid nanoparticles induce cell death of colorectal
cancer cells. Colloids Surf B Biointerfaces. 135:793–801. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Wu H, Li Y, Liu Z, Liu G, Guo Y, Hou
Z, Zhao Q, Chen D and Zhu X: Novel core-interlayer-shell DOX/ZnPc
Co-loaded MSNs@ pH-sensitive CaP@PEGylated liposome for enhanced
synergetic chemo-photodynamic therapy. Pharm Res. 35:572018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gupta B, Ramasamy T, Poudel BK, Pathak S,
Regmi S, Choi JY, Son Y, Thapa RK, Jeong JH, Kim JR, et al:
Development of bioactive PEGylated nanostructured platforms for
sequential delivery of doxorubicin and imatinib to overcome drug
resistance in metastatic tumors. ACS Appl Mater Interfaces.
9:9280–9290. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tyagi P and Subramony JA: Nanotherapeutics
in oral and parenteral drug delivery: Key learnings and future
outlooks as we think small. J Control Release. 272:159–168. 2018.
View Article : Google Scholar
|
